Title : Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer.

Pub. Date : 2018

PMID : 29761158






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Ruxolitinib is an orally bioavailable receptor tyrosine inhibitor targeting JAK1 and JAK2. Tyrosine Janus kinase 1 Homo sapiens